Chest
Volume 147, Issue 3, March 2015, Pages 585-586
Journal home page for Chest

Editorials
Linking Genetics to ARDS Pathogenesis: The Role of the Platelet

https://doi.org/10.1378/chest.14-2701Get rights and content

References (14)

There are more references available in the full text version of this article.

Cited by (15)

  • Plasma Insulin-like Growth Factor Binding Protein 7 Contributes Causally to ARDS 28-Day Mortality: Evidence From Multistage Mendelian Randomization

    2021, Chest
    Citation Excerpt :

    Many indices at ICU admission reflect the severity of ARDS, including platelet count, Pao2/Fio2, bilirubin, and creatinine. Platelet count is believed to contribute to ARDS pathogenesis and prognosis through platelet involvement in the inflammatory response and disseminated intravascular coagulation.31,32 We previously showed that early-stage thrombocytopenia in critically ill patients is associated with the development of mortality in ARDS.33

  • Net alveolar fluid clearance is associated with lung morphology phenotypes in acute respiratory distress syndrome

    2016, Anaesthesia Critical Care and Pain Medicine
    Citation Excerpt :

    The recognition of ARDS phenotypes may even contribute towards shifting the ARDS phenotype paradigm [23] according to biology, as already found in other research areas: for example, phenotypes based on the presence or absence of Th2-dependent inflammation have been identified in asthma, with important mechanistic and therapeutic implications [24]. An endotype is defined as a subtype of a condition defined by a distinct functional and/or pathobiological mechanism [25]. In our study, an ARDS phenotype based on lung morphology was characterized with a more severe impairment of AFC, i.e. with the physiological measurement of the rate of resolution of alveolar oedema in ARDS [11,12,20].

View all citing articles on Scopus

FINANCIAL/NONFINANCIAL DISCLOSURES: The authors have reported to CHEST the following conflicts: Dr Christie has received funding from the National Institutes of Health to study glycobiology and ARDS. Dr Reilly has reported that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.

Reproduction of this article is prohibited without written permission from the American College of Chest Physicians. See online for more details.

View full text